The authors suggested that the CXCL13/CXCR5 axis may have pathogenetic importance and that the PD-1+CXCL13+ T cells may be a potential treatment target in lymphocyte-rich cHL [30]. This evidence concerns the gene CXCR5 and classic Hodgkin lymphoma.